Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF ...

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...

Biogen Inc.BIIB announced that its biosimilar version of AbbVie, Inc.'s ABBV top-selling blockbuster drug, Humira has been approved by the European Commission. The biosimilar will be marketed by the ...

According to a Biogen press release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Biogen’s Imraldi®, a proposed ...

The forces of competition are mounting against Humira, the world’s best-selling drug at $16 billion in global sales, with approval of a second biosimilar in Europe. The European Commission gave its ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar ...

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

AbbVie, Inc.ABBV has signed a non-exclusive licensing deal with Mylan MYL regarding the latter's proposed biosimilar version of AbbVie's blockbuster arthritis drug, Humira, in the United States. Per ...

Samsung Bioepis Co. said Thursday it has reached a settlement with AbbVie Inc. that will allow it to market a near-replica version of rheumatoid-arthritis treatment Humira, one of the world’s ...

In addition, efficacy and injection site reactions/infusion related reactions (ISR/IRR) were evaluated in relation to the presence of ADAb. Data suggested that the development of ADAb is associated ...